| ［1］ |
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71（3）: 209-249.
|
| ［2］ |
国际肝胆胰协会中国分会, 中华医学会外科学分会肝脏外科学组, 中国临床肿瘤学会（CSCO）肝癌专家委员会. 肝细胞癌免疫联合治疗多学科中国专家共识（2023版）[J]. 中华消化外科杂志, 2023, 22（3）: 293-315.
|
| ［3］ |
Llovet JM, Mas X, Aponte JJ, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation[J]. Gut, 2002, 50（1）: 123-128.
|
| ［4］ |
中华医学会器官移植学分会, 中国医师协会器官移植医师分会肝移植学组, 中国康复医学会器官移植康复专业委员会. 中国肝癌肝移植受者免疫检查点抑制剂应用专家共识（2024版）[J]. 中华器官移植杂志, 2024, 45（7）: 415-431.
|
| ［5］ |
Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7（1）: 6.
|
| ［6］ |
肖治宇, 陈亚进. 肝胆肿瘤新辅助治疗的模式及方案选择[J]. 中国实用外科杂志, 2023, 43（3）: 276-280.
|
| ［7］ |
Marino R, Hassan AT, Fagenson A, et al. Liver transplantation for hepatocellular carcinoma following immunotherapy[J]. Curr Opin Organ Transplant, 2025, 30（4）: 242-250.
|
| ［8］ |
Kittai AS, Oldham H, Cetnar J, et al. Immune checkpoint inhibitors in organ transplant patients[J]. J Immunother, 2017, 40（7）: 277-281.
|
| ［9］ |
国家卫生健康委员会医政司. 原发性肝癌诊疗指南（2024年版）[J/OL]. 中华普通外科学文献（电子版）, 2024, 18(6): 385-410.
|
| ［10］ |
Reig M, Forner A, Rimola J, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update[J]. J Hepatol, 2022, 76（3）: 681-693.
|
| ［11］ |
De Stefano N, Patrono D, Colli F, et al. Liver transplantation for hepatocellular carcinoma in the era of immune checkpoint inhibitors[J]. Cancers（Basel）, 2024, 16（13）: 2374.
|
| ［12］ |
Tabrizian P, Holzner ML, Ajmera V, et al. Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: the multicenter VITALITY study[J]. J Hepatol, 2025, 82（3）: 512-522.
|
| ［13］ |
Schwenk L, Rauchfuß F, Ali-Deeb A, et al. Individualized curative treatment for malignant diseases through liver transplantation[J]. Chirurgie（Heidelb）, 2024, 95（2）: 122-128.
|
| ［14］ |
Ortiz V, Loeuillard E. Rethinking immune check point inhibitors use in liver transplantation: implications and resistance[J]. Cell Mol Gastroenterol Hepatol, 2025, 19（1）: 101407.
|
| ［15］ |
Braun F, Schäfer JP, Dobbermann H, et al. Hepatocellular carcinoma[J]. Chirurgie（Heidelb）, 2022, 93（7）: 635-643.
|
| ［16］ |
Davis L, Casselbury MB, Wilson S. Checkpoint inhibitor therapy: immune-related adverse event management[J]. Nursing, 2024, 54（11）: 26-33.
|
| ［17］ |
Liu Z, Zhu Y, Xie H, et al. Immune-mediated hepatitis induced by immune checkpoint inhibitors: current updates and future perspectives[J]. Front Pharmacol, 2023, 9（13）: 1077468.
|
| ［18］ |
Mok K, Wu C, Chan S, et al. Clinical management of gastrointestinal and liver toxicities of immune checkpoint inhibitors[J]. Clin Colorectal Cancer, 2024, 23（1）: 4-13.
|
| ［19］ |
Triantafyllou E, Gudd CLC, Possamai LA. Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management[J]. Nat Rev Gastroenterol Hepatol, 2025, 22（2）: 112-126.
|
| ［20］ |
Werner W, Kuzminskaya M, Lurje I，et al. Overcoming resistance to immune checkpoint blockade in liver cancer with combination therapy: stronger together?[J]. Semin Liver Dis, 2024, 44（2）: 159‐179.
|
| ［21］ |
Trifylli EM, Koustas E, Papadopoulos N, et al. An insight into the novel immunotherapy and targeted therapeutic strategies for hepatocellular carcinoma and cholangiocarcinoma[J]. Life, 2022, 12（5）: 665.
|
| ［22］ |
Qiu S, Zong Z, He K. Rescued with T and B lymphocytes depletion therapy for immune checkpoint inhibitor-associated transplant rejection[J]. Immunotherapy, 2025, 17（10）: 697-701.
|
| ［23］ |
Chen GH, Wang GB, Huang F, et al. Pretransplant use of toripalimab for hepatocellular carcinoma resulting in fatal acute hepatic necrosis in the immediate postoperative period[J]. Transpl Immunol, 2021, 66: 101386.
|
| ［24］ |
Rezaee-Zavareh MS, Yeo YH, Wang T, et al. Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis[J]. J Hepatol, 2025, 82（1）: 107-119.
|
| ［25］ |
Wassmer CH, El Hajji S, Papazarkadas X, et al. Immunotherapy and liver transplantation: A narrative review of basic and clinical data[J]. Cancers（Basel）, 2023, 15（18）: 4574.
|
| ［26］ |
Kuo FC, Chen CY, Lin NC, et al. Optimizing the safe washout period for liver transplantation following immune checkpoint inhibitors with atezolizumab，nivolumab，or pembrolizumab[J]. Transplant Proc, 2023, 55（4）: 878-883.
|
| ［27］ |
Tabrizian P, Yu A, Debnath N, et al. Immunotherapy and liver transplantation: the future or the failure?[J]. Surg Clin North Am, 2024, 104（1）: 163-182.
|
| ［28］ |
Lee BT, Fiel MI, Schiano TD. Antibody-mediated rejection of the liver allograft: An update and a clinico-pathological perspective[J]. J Hepatol, 2021, 75（5）: 1203-1216.
|
| ［29］ |
Filgueira NA. Hepatocellular carcinoma recurrence after liver transplantation: risk factors，screening and clinical presentation[J]. World J Hepatol, 2019, 11（3）: 261-272.
|
| ［30］ |
Bodzin AS, Lunsford KE, Markovic D, et al. Predictingmortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics[J]. Ann Surg, 2017, 266（1）: 118-125.
|
| ［31］ |
Ho CM, Chen HL, Hu RH, et al. Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: A review from a transplant oncology perspective[J]. Ther Adv Med Oncol, 2019, 26（11）: 1758835919843463.
|
| ［32］ |
Abdel-Wahab N, Safa H, Abudayyeh A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: An institutional experience and a systematic review of the literature[J]. J Immunother Cancer, 2019, 7（1）: 106.
|
| ［33］ |
Yao RR, Zhang QB, Ge MX, et al. The safety and efficacy of atezolizumab for recurrent primary liver cancer after liver transplantation[J]. Discov Oncol, 2025, 16（1）: 553.
|
| ［34］ |
Zhang P, Zhu G, Li L, et al. Immune checkpoint inhibitor therapy for malignant tumors in liver transplantation recipients: A systematic review of the literature[J]. Transplant Rev（Orlando）, 2022，36（4）: 100712.
|
| ［35］ |
Gassmann D, Weiler S, Mertens JC, et al. Liver allograft failure after Nivolumab treatment-A case report with systematic literature research[J]. Transplant Direct, 2018, 4（8）: e376.
|
| ［36］ |
Kumar V, Shinagare AB, Rennke HG, et al. The safety and efficacy of checkpoint inhibitors in transplant recipients: A case series and systematic review of literature[J]. Oncologist，2020, 25（6）: 505-514.
|
| ［37］ |
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated，PD-L1-positive，advanced non-small-cell lung cancer（KEYNOTE-010）: A randomised controlled trial[J]. Lancet, 2016, 387（10027）: 1540-1550.
|
| ［38］ |
Agrawal S, Feng Y, Roy A, et al. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy[J]. J Immunother Cancer, 2016, 15（4）: 72-82.
|
| ［39］ |
Mardomi A, Mohammadi N, Khosroshahi HT, et al. An update on potentials and promises of T cell co-signaling molecules in transplantation[J]. J Cell Physiol, 2020, 235（5）: 4183-4197.
|
| ［40］ |
Abdelrahim M, Esmail A, Saharia A, et al. Utilization of immunotherapy for the treatment of hepatocellular carcinoma in the peri-transplant setting: transplant oncology view[J]. Cancers（Basel）, 2022, 14（7）: 1760.
|
| ［41］ |
Friend BD, Venick RS, McDiarmid SV, et al. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma[J]. Pediatr Blood Cancer, 2017, 64（12）: 26682.
|
| ［42］ |
Munker S, De Toni EN. Use of checkpoint inhibitors in liver transplant recipients[J]. United European Gastroenterol J, 2018, 6（7）: 970-973.
|
| ［43］ |
Xie M, Dang ZP, Sun XG, et al. An analysis report on the application of immune checkpoint inhibitors after liver transplantation[J]. Ther Adv Chronic Dis, 2022, 19（13）: 20406223221099334.
|
| ［44］ |
Rimassa L, Finn RS, Sangro B. Combination immunotherapy for hepatocellular carcinoma[J]. J Hepatol, 2023, 79（2）: 506-515.
|